Jean-Philippe Michot

Suggest Changes
Learn More
PURPOSE Gastrointestinal stromal tumors (GIST) are frequently associated with gain-of-function mutations of KIT, which can be inhibited by imatinib both in vitro and in vivo. The survival of patients(More)
  • 1